mitomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, nucleotoxic agents 1819 50-07-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mitomycin
  • mutamycin
  • Mitomycin C
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
  • Molecular weight: 334.33
  • Formula: C15H18N4O5
  • CLOGP: -0.80
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 146.89
  • ALOGS: -1.52
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 24, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 102.63 30.97 109 1914 474317 50128784
Conjunctival filtering bleb leak 95.64 30.97 11 2012 6 50603095
Haemolytic uraemic syndrome 82.31 30.97 19 2004 2300 50600801
Pulmonary veno-occlusive disease 80.38 30.97 16 2007 959 50602142
Malignant neoplasm progression 57.36 30.97 35 1988 68089 50535012
Scleral thinning 57.29 30.97 7 2016 11 50603090
Mucosal inflammation 56.73 30.97 29 1994 40113 50562988
Iris transillumination defect 53.76 30.97 8 2015 81 50603020
Neutropenia 52.61 30.97 45 1978 147920 50455181
Thrombocytopenia 51.97 30.97 42 1981 127631 50475470
Leukopenia 50.04 30.97 32 1991 67496 50535605
Eye infection toxoplasmal 44.60 30.97 8 2015 272 50602829
Bladder perforation 42.84 30.97 7 2016 135 50602966
Hypotony of eye 42.65 30.97 7 2016 139 50602962
Necrotising scleritis 42.65 30.97 7 2016 139 50602962
Tractional retinal detachment 41.82 30.97 6 2017 46 50603055
Radiation skin injury 41.13 30.97 9 2014 854 50602247
Rhegmatogenous retinal detachment 38.66 30.97 6 2017 82 50603019
Extravasation 38.38 30.97 10 2013 1992 50601109
Pancytopenia 37.04 30.97 29 1994 84001 50519100
Disease progression 33.68 30.97 29 1994 95837 50507264
Conjunctival erosion 32.98 30.97 5 2018 58 50603043

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 127.42 31.09 120 1671 300680 29272056
Conjunctival filtering bleb leak 82.45 31.09 10 1781 6 29572730
Bladder perforation 81.24 31.09 14 1777 244 29572492
Iris hypopigmentation 63.18 31.09 9 1782 40 29572696
Scleral thinning 56.66 31.09 7 1784 6 29572730
NPM1 gene mutation 54.69 31.09 9 1782 117 29572619
Bronchiolitis obliterans syndrome 51.99 31.09 9 1782 161 29572575
Chimerism 49.24 31.09 9 1782 222 29572514
Post embolisation syndrome 44.98 31.09 7 1784 62 29572674
Bladder necrosis 43.57 31.09 5 1786 0 29572736
Scrotal ulcer 39.26 31.09 8 1783 353 29572383
Gastric perforation 37.79 31.09 11 1780 2175 29570561
Hypotony of eye 35.23 31.09 6 1785 97 29572639
Eosinophilic cystitis 34.78 31.09 5 1786 24 29572712
Blood immunoglobulin G decreased 34.78 31.09 9 1782 1150 29571586
Extravasation 31.51 31.09 9 1782 1663 29571073
Steroid diabetes 31.36 31.09 9 1782 1692 29571044
Conjunctival bleb 31.19 31.09 4 1787 6 29572730

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 185.52 26.79 206 3632 632600 63862294
Conjunctival filtering bleb leak 173.89 26.79 21 3817 12 64494882
Scleral thinning 143.26 26.79 18 3820 21 64494873
Bladder perforation 120.23 26.79 20 3818 284 64494610
Hypotony of eye 111.02 26.79 18 3820 216 64494678
Scleromalacia 87.31 26.79 10 3828 0 64494894
Pulmonary veno-occlusive disease 78.53 26.79 18 3820 1410 64493484
Iris hypopigmentation 77.57 26.79 11 3827 48 64494846
Mucosal inflammation 71.08 26.79 45 3793 62539 64432355
NPM1 gene mutation 60.93 26.79 10 3828 130 64494764
Haemolytic uraemic syndrome 60.05 26.79 18 3820 4003 64490891
Conjunctival erosion 56.30 26.79 9 3829 98 64494796
Bronchiolitis obliterans syndrome 54.59 26.79 10 3828 254 64494640
Chimerism 54.15 26.79 10 3828 266 64494628
Encapsulating peritoneal sclerosis 54.06 26.79 12 3826 813 64494081
Iris transillumination defect 54.01 26.79 9 3829 129 64494765
Eosinophilic cystitis 53.21 26.79 8 3830 56 64494838
Post embolisation syndrome 51.84 26.79 8 3830 68 64494826
Neutropenia 51.29 26.79 67 3771 239557 64255337
Extravasation 50.81 26.79 15 3823 3165 64491729
Gastric perforation 49.30 26.79 15 3823 3508 64491386
Thrombocytopenia 48.55 26.79 63 3775 223738 64271156
Radiation skin injury 48.36 26.79 12 3826 1318 64493576
Bladder necrosis 44.59 26.79 6 3832 16 64494878
Necrotising scleritis 44.15 26.79 8 3830 191 64494703
Leukopenia 43.81 26.79 41 3797 101201 64393693
Conjunctival bleb 43.36 26.79 6 3832 21 64494873
Pupillary disorder 43.32 26.79 9 3829 445 64494449
Endophthalmitis 43.10 26.79 15 3823 5350 64489544
Scrotal ulcer 40.63 26.79 8 3830 301 64494593
Blebitis 38.16 26.79 5 3833 10 64494884
Eye infection toxoplasmal 37.00 26.79 8 3830 479 64494415
Choroidal detachment 36.15 26.79 8 3830 534 64494360
Tractional retinal detachment 36.14 26.79 6 3832 84 64494810
Palmar-plantar erythrodysaesthesia syndrome 35.91 26.79 22 3816 28797 64466097
Acute myeloid leukaemia recurrent 35.33 26.79 11 3827 2773 64492121
Pancytopenia 35.25 26.79 43 3795 143266 64351628
Chemical cystitis 34.92 26.79 4 3834 0 64494894
Visual acuity reduced 34.53 26.79 21 3817 27120 64467774
Acute promyelocytic leukaemia 33.31 26.79 9 3829 1379 64493515
Rhegmatogenous retinal detachment 33.28 26.79 6 3832 139 64494755
Hepatic artery stenosis 33.08 26.79 6 3832 144 64494750
Steroid diabetes 31.61 26.79 10 3828 2656 64492238
Blood immunoglobulin G decreased 31.55 26.79 10 3828 2673 64492221
Second primary malignancy 31.02 26.79 15 3823 12322 64482572
Anterior chamber pigmentation 29.63 26.79 4 3834 11 64494883
Disease progression 29.29 26.79 39 3799 141641 64353253
Corneal oedema 28.66 26.79 9 3829 2334 64492560

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DC03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
CHEBI has role CHEBI:35610 antineoplastic agents
MeSH PA D000477 Alkylating Agents
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D003432 Cross-Linking Reagents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007202 Indicators and Reagents
MeSH PA D009676 Noxae
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Adenocarcinoma of pancreas indication 700423003 DOID:4074
Metastatic Gastric Cancer indication
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Malignant tumor of anus off-label use 363490009 DOID:14110
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Prevention of Recurrent Bladder Carcinoma off-label use
Corneal Conjunctival Intraepithelial Neoplasm off-label use
Stomatitis contraindication 61170000 DOID:9637
Acute infectious disease contraindication 63171007
Blood coagulation disorder contraindication 64779008 DOID:1247
Heart failure contraindication 84114007 DOID:6000
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Hemolytic uremic syndrome contraindication 111407006 DOID:12554
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Pulmonary Infiltrates contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.54 acidic
pKa2 10.39 Basic
pKa3 7.53 Basic
pKa4 4.95 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.2MG/VIAL MITOSOL MOBIUS THERAP N022572 Feb. 7, 2012 RX FOR SOLUTION TOPICAL 9539241 Jan. 2, 2028 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
0.2MG/VIAL MITOSOL MOBIUS THERAP N022572 Feb. 7, 2012 RX FOR SOLUTION TOPICAL 9649428 May 21, 2029 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2023 NEW PRODUCT
40MG/VIAL JELMYTO UROGEN PHARMA N211728 April 15, 2020 RX POWDER PYELOCALYCEAL April 15, 2027 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Indoleamine 2,3-dioxygenase 1 Enzyme Ki 4.60 CHEMBL

External reference:

IDSource
4018134 VUID
N0000146471 NUI
D00208 KEGG_DRUG
4018134 VANDF
C0002475 UMLSCUI
CHEBI:27504 CHEBI
CHEMBL105 ChEMBL_ID
D016685 MESH_DESCRIPTOR_UI
DB00305 DRUGBANK_ID
7089 IUPHAR_LIGAND_ID
3043 INN_ID
50SG953SK6 UNII
5746 PUBCHEM_CID
204298 RXNORM
1274 MMSL
140168 MMSL
1973 MMSL
5122 MMSL
d00305 MMSL
002660 NDDF
387331000 SNOMEDCT_US
59240002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9279 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9280 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 17 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-108 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-115 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-116 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-246 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-247 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 16729-248 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-518 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-519 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-520 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-995 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-996 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 67457-997 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 16 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-389 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 68001-391 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
MITOMYCIN Human Prescription Drug Label 1 68083-483 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 15 sections
MITOMYCIN Human Prescription Drug Label 1 68083-484 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 15 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-001 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-002 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 18 sections
MUTAMYCIN HUMAN PRESCRIPTION DRUG LABEL 1 69448-003 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 mg INTRAVENOUS ANDA 18 sections
Mitomycin HUMAN PRESCRIPTION DRUG LABEL 1 72819-152 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 18 sections